Utidelone
Utidelone is Biostar Pharmaceuticals' epothilone chemotherapy, approved in China in 2021 with capecitabine for advanced breast cancer after anthracyclines and taxanes.
Overview
Utidelone is a genetically engineered epothilone analogue produced by fermentation, developed by Biostar Pharmaceuticals in Chengdu. The NMPA approved it in March 2021 in combination with capecitabine for recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane, after a phase 3 trial showed longer progression-free and overall survival than capecitabine alone. An oral form is in later trials.
Binds tubulin and locks microtubules in place so that dividing cells cannot complete mitosis; it works in cells that have become resistant to taxanes. Connects to Tubulin (microtubules).
1.Utidelone slips into a pocket on Tubulin (microtubules).
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2021 | Recurrent or metastatic breast cancer after anthracycline and taxane, with capecitabine |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Utidelone" OR ABSTRACT:"Utidelone" OR TITLE:"UTD1" OR ABSTRACT:"UTD1" OR TITLE:"Youheng" OR ABSTRACT:"Youheng") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Utidelone, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBenmelstobart
Shares the tags china, nmpa-approved.
- TreatmentFlumatinib
Shares the tags china, nmpa-approved.
- TreatmentGumarontinib
Shares the tags china, nmpa-approved.
- TreatmentH101 oncolytic adenovirus
Shares the tags china, nmpa-approved.
- TreatmentInetetamab
Shares the tags china, nmpa-approved.
- TreatmentIparomlimab and tuvonralimab
Shares the tags china, nmpa-approved.
- TreatmentIruplinalkib
Shares the tags china, nmpa-approved.
- TreatmentLinperlisib
Shares the tags china, nmpa-approved.